Antihyperglycaemic drugs for long-term management of acute coronary syndromes

Several randomised controlled trials indicate a cardiovascular benefit with the use of sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonistsBuse, 2020Neal, 2017Visseren, 2021Wiviott, 2019Zinman, 2015. Therefore, consider these drug classes for patients with diabetes. See SGLT2 inhibitors and GLP-1 receptor agonists for more information.